Loading...
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vi...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382939/ https://ncbi.nlm.nih.gov/pubmed/22538851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-400929 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|